Martin R. Gaudinski - Concepedia

Author

Martin R. Gaudinski

Also Known As

Adrian Creanga, M. Gaudinski, Martin Gaudinski, Martin R Gaudinski, Martin R. Gaudinski, Martin Robert Gaudinski, Mary E. Enama

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

National Institutes of Health National Institute of Allergy and Infectious Diseases University of California San Diego Frederick National Laboratory for Cancer Research Walter Reed Army Institute of Research

About

Martin R. Gaudinski is an author at National Institutes of Health specializing in medicine, immunology, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	964
2	Immunology	13	13	964
3	Health Sciences	1	1	50
4	Neurology	1	1	50
5	Neuroscience	1	1	50

Martin R. Gaudinski

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates Kizzmekia S. Corbett, Barbara J. Flynn, Kathryn E. Foulds, New England Journal of Medicine	2020	1.1K
A proof of concept for structure-based vaccine design targeting RSV in humans Michelle C. Crank, Tracy J. Ruckwardt, Man Chen, Science	2019	323
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials Martin R. Gaudinski, Katherine V. Houser, Kaitlyn M. Morabito, The Lancet	2017	298
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults Martin R. Gaudinski, Emily E. Coates, Katherine V. Houser, PLoS Medicine	2018	249
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants Lingshu Wang, Tongqing Zhou, Yi Zhang, Science	2021	212
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial Katherine V. Houser, Grace Chen, Cristina Carter, Nature Medicine VaccinologyVaccine SafetyVaccinationCross-protectionVaccine Development	2022	153
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization Nicole A. Doria‐Rose, Xiaoying Shen, Stephen D. Schmidt, VaccinationVaccine SafetyVaccine DevelopmentMedicineVaccine Surveillance	2021	129
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study Martin R. Gaudinski, Emily E. Coates, Laura Novik, The Lancet VaccinationOpen-label Phase 1Vaccine TargetImmunologyAntiviral Drug Development	2019	123
Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali Kassoum Kayentao, Aïssata Ongoïba, Anne C Preston, New England Journal of Medicine	2022	117
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria Richard L Wu, Azza H. Idris, Nina M. Berkowitz, New England Journal of Medicine	2022	114

Page 1